Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns

Rheumatology (United Kingdom)

Volumn 52, Issue 4, 2013, Pages 631-635

  van de Stadt, Lotte A ^a,b   van Schouwenburg, Pauline A ^a   Bryde, Suzanne ^a   Kruithof, Simone ^a   van Schaardenburg, Dirkjan ^b,c   Hamann, Dörte ^d   Wolbink, Gertjan ^a,b   Rispens, Theo ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Sanquin Diagnostiek   (Netherlands)

Author keywords

Acpa; Autoantibodies; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FIBRINOGEN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RNA;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CLONE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOMATIC MUTATION; SUPERNATANT;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; PEPTIDES, CYCLIC;

EID: 84875614928     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes371     Document Type: Article

References (18)

1. Nielen MM, van SD, Reesink HW et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
2. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
3. Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
4. Kuhn KA, Kulik L, Tomooka B et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
5. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350: 2572-81.
6. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
7. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003;25: 1106-18.
8. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84.
9. Sebbag M, Moinard N, Auger I et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006;36:2250-63.
10. Kinloch A, Tatzer V, Wait R et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421-9.
11. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-94.
12. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
13. van de Stadt LA, de Koning MH, van de Stadt RJ et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011;63:3226-33.
14. Suwannalai P, Scherer HU, van der Woude D et al. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 2011;70:373-9.
15. Suwannalai P, van de Stadt LA, Radner H et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012; 64:1323-8.
16. van de Stadt LA, van der Horst AR, de Koning MHMT et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011;70: 128-33.
17. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
18. Raats JM, Wijnen EM, Pruijn GJ, van den Hoogen FH, van Venrooij WJ. Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis. J Rheumatol 2003;30: 1696-711.